首页> 外文期刊>Journal of critical care >The use of IgM-enriched immunoglobulin in adult patients with sepsis
【24h】

The use of IgM-enriched immunoglobulin in adult patients with sepsis

机译:富含IgM富含免疫球蛋白在成年患者中的脓毒症患者

获取原文
获取原文并翻译 | 示例
           

摘要

The administration of intravenous immunoglobulins (IVIG) is one of the adjunct therapies investigated and applied to sepsis patients, with the first studies being published nearly four decades ago. Intravenous immunoglobulin preparations have several mechanisms of action e.g. antigen neutralization, Fc-receptor blockade on phagocytic cells, modulation of cytokine responses andmodulation of immune cell functions. The currently available evidence suggesting the use of intravenous immunoglobulins in sepsis is weak, but results from recent trials and systematic metanalyses seem more promising for the use of intravenous IgM-enriched immunoglobulins (IVIgGM) in septic patients. Nevertheless, the results of studies examining its value are contradicting. The purpose of this review is to summarize and present, clearly and thoroughly, the currently available data regarding established and future potential clinical uses of IVIgGM in patients with sepsis. (C) 2018 Elsevier Inc. All rights reserved.
机译:静脉注射免疫球蛋白(IVIG)的给药是研究和应用于败血症患者的辅助疗法之一,第一次研究近几十年前发表。静脉内免疫球蛋白制剂具有几种作用机制。抗原中和,Fc受体阻断对吞噬细胞,调节细胞因子反应和免疫细胞功能的调节。目前可用的证据表明在败血症中使用静脉内免疫球蛋白的弱势,但最近试验和系统的MetanAlyses的结果似乎更有前景在脓毒症患者中使用静脉注射的IgM富含免疫球蛋白(IVIGGM)。然而,研究其价值的研究结果是相互矛盾的。本综述的目的是概述和彻底,清晰,彻底,目前可用的数据有关IVIGGM患者患者患者的既定和未来潜在临床用途。 (c)2018年Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号